Impact of Low-Dose Prasugrel on Platelet Reactivity in Chronic Phase of Post-Percutaneous Coronary Intervention (CHAPERON): a Prospective Cohort Study-Reference-Cited by-同舟云学术

Impact of Low-Dose Prasugrel on Platelet Reactivity in Chronic Phase of Post-Percutaneous Coronary Intervention (CHAPERON): a Prospective Cohort Study

Published:2023-04-25 Issue: Volume: Page:
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Fukase Tatsuya,Doi Shinichiro,Dohi Tomotaka^ORCID,Koike Takuma,Nishio Ryota,Yasuda Hidetoshi,Takeuchi Mitsuhiro,Takahashi Norihito,Chikata Yuichi,Endo Hirohisa,Nishiyama Hiroki,Okai Iwao,Iwata Hiroshi,Okazaki Shinya,Daida Hiroyuki,Suwa Satoru,Minamino Tohru,Miyauchi Katsumi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10557-023-07454-z.pdf

Reference38 articles.

1. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–71.

2. Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371–82.

3. Natsuaki M, Morimoto T, Yamaji K, et al. Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc. 2018;7:e008708.

4. Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60:1340–8.

5. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510–22.